William Blair Brokers Boost Earnings Estimates for ResMed

ResMed Inc. (NYSE:RMD - Free Report) - William Blair boosted their Q3 2025 earnings estimates for shares of ResMed in a report issued on Friday, December 6th. William Blair analyst M. Andrew now expects that the medical equipment provider will post earnings per share of $2.37 for the quarter, up from their previous estimate of $2.33. The consensus estimate for ResMed's current full-year earnings is $9.34 per share. William Blair also issued estimates for ResMed's Q4 2025 earnings at $2.44 EPS and FY2025 earnings at $9.30 EPS.

ResMed (NYSE:RMD - Get Free Report) last announced its earnings results on Thursday, October 24th. The medical equipment provider reported $2.20 EPS for the quarter, topping the consensus estimate of $2.03 by $0.17. ResMed had a net margin of 23.15% and a return on equity of 25.53%. The company had revenue of $1.22 billion during the quarter, compared to analysts' expectations of $1.19 billion. During the same period last year, the company posted $1.64 earnings per share. The business's revenue for the quarter was up 11.1% on a year-over-year basis.

Other research analysts have also recently issued reports about the stock. Needham & Company LLC reiterated a "hold" rating on shares of ResMed in a report on Friday, October 25th. Baird R W raised shares of ResMed to a "strong-buy" rating in a research report on Tuesday, September 24th. StockNews.com raised shares of ResMed from a "hold" rating to a "buy" rating in a research report on Tuesday, October 15th. KeyCorp boosted their price objective on shares of ResMed from $251.00 to $266.00 and gave the company an "overweight" rating in a research report on Friday, October 25th. Finally, Royal Bank of Canada boosted their price objective on shares of ResMed from $224.00 to $232.00 and gave the company a "sector perform" rating in a research report on Friday, October 25th. One investment analyst has rated the stock with a sell rating, five have issued a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, the stock has an average rating of "Moderate Buy" and an average price target of $225.70.

ResMed Trading Up 1.6 %

Shares of RMD traded up $3.86 during midday trading on Monday, hitting $245.27. The stock had a trading volume of 212,633 shares, compared to its average volume of 1,024,090. ResMed has a fifty-two week low of $162.18 and a fifty-two week high of $260.49. The business has a 50-day simple moving average of $242.30 and a two-hundred day simple moving average of $226.57. The firm has a market cap of $36.01 billion, a P/E ratio of 31.97, a price-to-earnings-growth ratio of 1.75 and a beta of 0.68. The company has a current ratio of 2.92, a quick ratio of 1.91 and a debt-to-equity ratio of 0.13.

Institutional Investors Weigh In On ResMed

Several large investors have recently modified their holdings of the stock. American Trust acquired a new position in ResMed during the 3rd quarter worth about $690,000. Franklin Resources Inc. lifted its position in shares of ResMed by 56.5% during the third quarter. Franklin Resources Inc. now owns 174,113 shares of the medical equipment provider's stock worth $41,909,000 after purchasing an additional 62,882 shares in the last quarter. Tidal Investments LLC grew its stake in shares of ResMed by 738.4% during the third quarter. Tidal Investments LLC now owns 104,938 shares of the medical equipment provider's stock valued at $25,617,000 after purchasing an additional 92,422 shares during the last quarter. Wilmington Savings Fund Society FSB bought a new position in ResMed in the 3rd quarter worth approximately $193,000. Finally, World Investment Advisors LLC acquired a new position in ResMed during the 3rd quarter worth $541,000. 54.98% of the stock is currently owned by institutional investors.

Insider Transactions at ResMed

In other ResMed news, CEO Michael J. Farrell sold 14,683 shares of the business's stock in a transaction on Monday, October 7th. The shares were sold at an average price of $231.91, for a total value of $3,405,134.53. Following the sale, the chief executive officer now owns 464,169 shares of the company's stock, valued at $107,645,432.79. The trade was a 3.07 % decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, Director Witte Jan De sold 796 shares of the company's stock in a transaction dated Tuesday, November 12th. The shares were sold at an average price of $248.81, for a total transaction of $198,052.76. Following the completion of the sale, the director now directly owns 6,723 shares in the company, valued at approximately $1,672,749.63. The trade was a 10.59 % decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders sold 52,725 shares of company stock worth $12,516,248. 0.71% of the stock is owned by insiders.

ResMed Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Thursday, December 12th. Stockholders of record on Thursday, November 7th will be paid a $0.53 dividend. This represents a $2.12 dividend on an annualized basis and a dividend yield of 0.86%. The ex-dividend date is Thursday, November 7th. ResMed's payout ratio is 28.08%.

About ResMed

ResMed Inc develops, manufactures, distributes, and markets medical devices and cloud-based software applications for the healthcare markets. The company operates in two segments, Sleep and Respiratory Care, and Software as a Service. It offers various products and solutions for a range of respiratory disorders, including ApneaLink Air, a portable diagnostic device that measures oximetry, respiratory effort, pulse, nasal flow, and snoring; and NightOwl, a portable, cloud-connected, and disposable diagnostic device that measures AHI based on derived peripheral arterial tone, actigraphy, and oximetry over several nights.